In the 1980s, Nishizuka and others discovered that PKC isozymes are the receptor for the tumor-promoting phorbol esters (Castagna et al., 1982), which formed the basis of the dogma that PKC isozymes act as oncogenes. The gene discussed is PRRT2; the disease is neoplasm.